Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asger Lund

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Diabetes, Obesity & Metabolism|June 17, 2020
Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trialNicklas J Johansen, Thomas F Dejgaard, Asger Lund, et al.
Metabolic Syndrome and Related Disorders|October 17, 2018
Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control SubjectsMia Demant, Jonatan I Bagger, Malte P Suppli, et al.
Diabetes Care|January 18, 2020
No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 DiabetesNatasha C Bergmann, Lærke S Gasbjerg, Sebastian M Heimbürger, et al.
Diabetologia|January 27, 2019
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover studyNatasha C Bergmann, Asger Lund, Lærke S Gasbjerg, et al.
Diabetes|January 25, 2020
Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic SteatosisMalte P Suppli, Jonatan I Bagger, Asger Lund, et al.
Diabetologia|May 13, 2020
The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trialCaroline T B Juel, Asger Lund, Maria M Andersen, et al.
Endocrine Connections|November 30, 2020
No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effectDavid S Mathiesen, Jonatan I Bagger, Katrine B Hansen, et al.
The Lancet. Diabetes & Endocrinology|March 6, 2020
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trialNicklas J Johansen, Thomas F Dejgaard, Asger Lund, et al.
Ebiomedicine|June 21, 2016
Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human PlasmaNicolai J Wewer Albrechtsen, Daniel Hornburg, Reidar Albrechtsen, et al.
Diabetes|May 26, 2016
Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65:585-597Asger Lund, Jonatan I Bagger, Nicolai J Wewer Albrechtsen, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Diabetes, Obesity & Metabolism|June 17, 2020
Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trialNicklas J Johansen, Thomas F Dejgaard, Asger Lund, et al.
Metabolic Syndrome and Related Disorders|October 17, 2018
Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control SubjectsMia Demant, Jonatan I Bagger, Malte P Suppli, et al.
Diabetes Care|January 18, 2020
No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 DiabetesNatasha C Bergmann, Lærke S Gasbjerg, Sebastian M Heimbürger, et al.
Diabetologia|January 27, 2019
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover studyNatasha C Bergmann, Asger Lund, Lærke S Gasbjerg, et al.
Diabetes|January 25, 2020
Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic SteatosisMalte P Suppli, Jonatan I Bagger, Asger Lund, et al.
Diabetologia|May 13, 2020
The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trialCaroline T B Juel, Asger Lund, Maria M Andersen, et al.
Endocrine Connections|November 30, 2020
No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effectDavid S Mathiesen, Jonatan I Bagger, Katrine B Hansen, et al.
The Lancet. Diabetes & Endocrinology|March 6, 2020
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trialNicklas J Johansen, Thomas F Dejgaard, Asger Lund, et al.
Ebiomedicine|June 21, 2016
Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human PlasmaNicolai J Wewer Albrechtsen, Daniel Hornburg, Reidar Albrechtsen, et al.
Diabetes|May 26, 2016
Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65:585-597Asger Lund, Jonatan I Bagger, Nicolai J Wewer Albrechtsen, et al.
Pageof 6